Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear
Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.
You may also be interested in...
Sales of PCSK9 inhibitors have been improving, though are still low, and inclusion of lower LDL-C targets in practice guidelines coming this November would be a boost.
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.
Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.